Patents Assigned to Clinical Technologies, Inc.
  • Publication number: 20070169774
    Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned in the patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste.
    Type: Application
    Filed: March 23, 2007
    Publication date: July 26, 2007
    Applicant: Clinical Technologies, Inc.
    Inventors: Robert Johnson, Robert DuBose
  • Publication number: 20020121275
    Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned in the patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste.
    Type: Application
    Filed: May 15, 2001
    Publication date: September 5, 2002
    Applicant: CLINICAL TECHNOLOGIES, INC.
    Inventors: Robert Johnson, Robert DuBose
  • Patent number: 6363932
    Abstract: An aerosol medication delivery apparatus includes a fixed volume holding chamber which is constructed to allow for a uniformly mixed, concentrated bolus of medicated aerosol to be delivered with each breath. The device further includes a universal inlet, so that any standard small volume nebulizer, as well as any standard metered dose inhaler (MDI), may be utilized therewith. Also filtration can be added to address contaminated patient air and aerosol. A one-way valve is positioned between the holding chamber and a tee piece for attaching the holding chamber to a patient mouthpiece, to help control the loss of aerosol, and thereby reduce waste. The device is simply constructed of two molded plastic members, which are readily engaged to complete its assembly.
    Type: Grant
    Filed: July 6, 2000
    Date of Patent: April 2, 2002
    Assignee: Clinical Technologies, Inc.
    Inventors: Dennis Forchione, Robert Johnson
  • Patent number: 6063374
    Abstract: A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: May 16, 2000
    Assignee: Clinical Technologies, Inc.
    Inventors: Syed Zaki Salahuddin, Nickolas Chelyapov
  • Patent number: 5753490
    Abstract: A recombinant human immunodeficiency virus (rHIV) and recombinant mammalian cell-line (packaging systems) and a method for treating infection of cells by human immuneodeficiency virus HIV. rHIV, such as rHIV-1, comprises of a gene construction which includes a foreign gene. The expression of this gene is activated in human cells in the presence of wild-type HIV. This gene product can cause cell death in the presence of an appropriate drug, e.g. Acyclovir. This gene product is typically a viral thymidine kinase. rHIV is so constructed that it is unable to replicate by itself due to the absence of a regulatory gene that is necessary for its replication, such as tat or rev or both. The recombinant mammalian cell-line packaging system comprises in its genome a recombinant gene construction which typically includes a functional regulatory gene from HIV which is missing from rHIV, such as the tat or rev genes or both.
    Type: Grant
    Filed: November 28, 1995
    Date of Patent: May 19, 1998
    Assignee: Clinical Technologies, Inc.
    Inventors: Syed Zaki Salahuddin, Nickolas Chelyapov